Please assess the completion status of the following clinical trial:

Trial Title: LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All cases with evidence of atypical endometrial hyperplasia declining doing hysterectomy~Exclusion Criteria:~* Cases with evidence of associated endometrial cancer.~* Cases with simple hyperplasia without atypia.~* Patients failed to collect at least 2 endometrial samples during treatment course.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- levonorgestrel intrauterine system (LNG-IUD) (Type: ACTIVE_COMPARATOR): levonorgestrel intrauterine system (LNG-IUD) applied.~* Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~* Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~* Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis.
- Megestrol acetate (MA) (Type: ACTIVE_COMPARATOR): Megesterol arm will receive 160 mg daily~* Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~* Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~* Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).